S&P Futures
4,169.75 -21.75 (-0.52%) Dow Futures
34,108.00 +11.00 (+0.03%) Nasdaq Futures
12,654.00 -192.75 (-1.50%) Russell 2000 Futures
2,006.80 -1.10 (-0.05%) Crude Oil
75.70 -0.18 (-0.24%) Gold
1,928.90 -1.90 (-0.10%)
Emergent BioSolutions Inc. (EBS)
After hours:
Chart Events
Performance Outlook
| Previous Close | 13.65 |
| Open | 13.98 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1000 |
| Day's Range | 13.91 - 14.88 |
| 52 Week Range | 10.61 - 47.71 |
| Volume | |
| Avg. Volume | 1,024,276 |
| Market Cap | 725.873M |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | 17.74 |
| EPS (TTM) | 0.82 |
| Earnings Date | Apr 26, 2023 - May 01, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for EBS
Related Research
- Emergent Biosolutions, Inc.EBS: Raising target price to $11.00EMERGENT BIOSOLUTIONS INC has an Investment Rating of SELL; a target price of $11.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.RatingFair ValueEconomic Moat2 days agoArgus Research
- Reuters
UPDATE 1-FDA identifies recall of Emergent's decontamination kits as most serious
The U.S. Food and Drug Administration on Thursday classified the recall of Emergent BioSolutions Inc's skin decontamination lotion kits as the most serious type. Emergent had recalled kits with distribution dates between Oct. 4 and Oct. 14, 2022. The company's investigation showed that all kits, other than the recalled lots, met quality criteria and were suitable for use, Emergent said in a statement to Reuters.
- Reuters
FDA identifies recall of Emergent's decontamination kits as most serious
The U.S. Food and Drug Administration on Thursday classified the recall of Emergent BioSolutions Inc's skin decontamination lotion kits as the most serious type. The contract manufacturer began the recall of 3500 units of the kit in November, after receiving three customer complaints of leakage from the packets. Emergent said that so far no serious injuries or deaths related to the issue were reported.
- Reuters
U.S. FDA panel to review Emergent's OTC opioid overdose drug
The U.S. health regulator said on Tuesday its advisory panel will meet on Feb. 15 to review Emergent Biosolutions Inc's over-the-counter (OTC) nasal spray to treat suspected opioid overdoses. Emergent is seeking the Food and Drug Administration's (FDA)approval for the prescription-free sale of Narcan, its nasal spray form of the drug naloxone. Narcan is already cleared for the treatment of opioid overdose in the country.
